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Incorporation by coordination and release of the iron
chelator drug deferiprone from zinc-based
metal–organic frameworks†
Andrew D. Burrows,*a Monika Jurcic,a Luke L. Keenan,a Rebecca A. Lane,a
Mary F. Mahon,*a Mark R. Warren,b Harriott Nowell,b Michael Paradowskic and
John Spencer*c
A series of new zinc-based metal–organic framework materials has
been prepared in which deferiprone is incorporated as a chelating
ligand on infinite or tri-zinc secondary building units following
deprotonation. Deferiprone is immediately released from the
MOFs on treatments with 1 N hydrochloric acid or buffer, but slow
release is observed in ethanoic acid.
Metal–organic frameworks (MOFs) are attracting considerable
attention due to their potential for permanent porosity, and the
consequent applications of this in areas as diverse as hydrogen
storage, separations and heterogeneous catalysis.1 Since the first
report, in 2006, that bioactive molecules could be encapsulated
within the pores of MOFs and released slowly,2 there has been an
increased focus on using MOFs to control drug delivery.3 As an
alternative to including bioactive molecules as guests within pores
of a pre-formedMOF, it is also possible to use this kind ofmolecule
as a component of the framework itself.4 A number of examples
have been reported, including those in which nicotinate,5 glutarate6
and theophylline7 have been incorporated as linkers. Many MOFs
can be prepared with coordinatively unsaturatedmetal centres, and
small bioactive molecules such as NO have been incorporated into
such systems by coordination to these metal sites.8
In this communication, we report our initial studies on the
inclusion into MOFs of the iron chelator drug deferiprone (Hdfp),
which is used as an oral treatment for haemosiderosis (iron over-
load) that can occur as a consequence of regular blood transfusions
required in the treatment of conditions such as thalassaemiamajor
and haemochromatosis.9 Deferiprone has high selectivity for Fe3+
over other cations, and it is used clinically in Europe and Asia as an
orally active iron chelator. In addition, deferiprone possesses
antioxidant properties protecting against oxidative stress,10,11 and
recently it has been studied for potential application in the treat-
ment of neurodegenerative diseases such as Alzheimer’s.12
Despite its excellent bioavailability, deferiprone is known to have
a number of side eﬀects such as neutropenia and gastro-inestinal
disorders.Moreover, it ismetabolised (ca. 85%) byO-glucuronidation
to a biologically inactive, non-iron chelating 3-O-glucuronide con-
jugate.13 Methods to reduce O-conjugation in order to reduce
excretion are desirable, and incorporation within a framework
material provides a potential means of achieving this.
We selected zinc-based MOFs for study, since the aﬃnity of
deferiprone for zinc(II) is known to be relatively low,14 and zinc
MOFs generally decompose at low pH, which would be expected to
trigger deferiprone release. The reaction of Zn(NO3)26H2O with
1,4-benzenedicarboxylic acid (H2bdc) andHdfp in DMF at 100 1C for
24 h gave colourless block-shaped crystals, which were identified
through single crystal X-ray analysis as [Zn3(bdc)2(dfp)2]2DMF 1.‡
Compound 1 has a three-dimensional network structure in which
infinite zinc SBUs are bridged by the bdc linkers. The SBUs, shown in
Fig. 1a, contain two independent zinc centres – Zn(1) lies on an
inversion centres and is 6-coordinate, and bonded to four carboxylate
and two dfp oxygen atoms, all from different ligands. Zn(2) is
5-coordinate, and bonded to two carboxylate and three dfp oxygen
atoms, with one of the dfp ligands bidentate. The geometry of Zn(2)
lies between square planar and trigonal bipyramidal (t = 0.5915). Pairs
of carboxylate ligands bridge between Zn(1) and Zn(2), whereas dfp, a
deprotonated deferiprone, acts as a bidentate ligand on Zn(2), and a
monodentate ligand to two Zn(1) centres. The infinite SBUs run along
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the crystallographic a-axis, and are interconnected by the bdc linkers to
generate rhomboidal pores, intowhich the dfp ligands project (Fig. 1b).
The pores are also occupied by uncoordinated DMF molecules.
Changing the reaction solvent from DMF to water did not
aﬀord any MOF products, but changing it to a 5 : 1 mixture of
ethanol and water led to colourless rhomboidal crystals that
showed a diﬀerent powder X-ray diﬀraction (PXRD) pattern to
those of 1. On analysis by single crystal X-ray crystallography,
this product was identified as [Zn3(bdc)2(dfp)2(H2O)2] 2.
The structure of compound 2 is related to that of 1, with infinite
SBUs linked into a three-dimensional network by the bdc ligands.
There are, however, subtle diﬀerences in the coordination geo-
metries of the metal centres. Instead of pairs of carboxylate groups
bridging between Zn(1) and Zn(2), as observed in 1, only one
carboxylate does this, and Zn(1), which lies on an inversion centre,
maintains a 6-coordinate geometry by bonding to two water mole-
cules. Zn(2) is coordinated to a bidentate carboxylate in addition to a
bridging carboxylate, and as a consequence is 6-coordinate. As a
result of this coordination, the infinite SBUs are considerably more
puckered in 2 than they are in 1 (Fig. 2a), as witnessed by
Zn  Zn  Zn angles of 95.41 (cf. 152.91 for 1). Hydrogen bonds are
present between thewater hydrogen atoms and both carboxylate and
dfp oxygen atoms. Compound 2 exhibits similar rhomboidal pores
to those in 1 (Fig. 2b), though these are flattened, which is consistent
with the lack of inclusion of DMF. Use of a mixture of DMF and
water as the solvent gave a mixture of 1 and 2, as shown by PXRD.
The successful incorporation of deferiprone into the frame-
work of the MOFs led us to consider the role of the bridging
dicarboxylate, and to determine how the presence of functional
groups would aﬀect the structure. Consequently, the reaction
between Zn(NO3)26H2O and deferiprone was carried out in the
presence of 2-amino-1,4-benzenedicarboxylic acid (H2bdc-NH2)
and 2,5-dihydroxy-1,4-benzenedicarboxylic acid (H2bdc-(OH)2)
under similar conditions as those that gave the mixture of 1 and 2.
In the case of H2bdc-NH2, two types of crystals were again
observed in the product, and comparison of the PXRD patterns
with those from the mixture of 1 and 2 suggested the products were
the analogous compounds [Zn3(bdc-NH2)2(dfp)2]DMF 3 and
[Zn3(bdc-NH2)2(dfp)2(H2O)2] 4. Compound 3 was further charac-
terised by a single crystal X-ray analysis, which confirmed that it
had a very similar network structure to that of 1, with the amino
groups disordered over two positions on the benzene ring (see ESI†).
In the case of H2bdc-(OH)2, only one crystal type was observed in
the product. This was characterised crystallographically as [Zn3{bdc-
(OH)2}2(dfp)2(H2O)2]2DMF 5.‡ In contrast to 1–4, compound 5
adopts a two-dimensional network structure, with individual
Zn3(O2CR)4(dfp)2(H2O)2 SBUs inter-connected into sheets by the
dicarboxylate linkers. In the SBUs, Zn(1) and Zn(3) are each
coordinated to five oxygen atoms, two from carboxylate groups,
two from a bidentate dfp and a water molecule, with coordination
geometries close to trigonal bipyramidal (t = 0.75, 0.77) whereas
Zn(2), which lies on a two-fold rotation axis, is 6-coordinate,
bonding to four carboxylate and two bridging dfp oxygen atoms
(Fig. 3a). The water molecules serve to terminate the SBUs, and
prevent aggregation into the infinite SBUs observed for 1–3, though
these are linked together through hydrogen bonds. The bdc-(OH)2
linkers connect the SBUs into two-dimensional sheets (Fig. 3b),
which contain rhomboidal pores into which the dfp ligands project,
and the included DMF molecules are accommodated.
The tri-zinc units observed in 5, and in an aggregated form in
1–4, are a commonly observed motif in zinc MOFs, and have been
observed in a number of compounds.16–19 In these frameworks, the
SBU adopts a Zn3(O2CR)6 form, with carboxylate groups radiating
out from the Zn3 ‘spoke’ at approximately 601 angles. In 1–5, dfp
linkers take the place of two of the carboxylates, so that the four
carboxylate groups radiating from the SBU are at angles of 601 and
1201 from each other, which in combination with the linear linkers
generates the rhomboidal pores observed.
LCMS analyses showed that 1 gave no release of deferiprone on
suspension in either DMSO or methanol, and was stable for more
than 1 week in the presence of these solvents. Release of deferiprone
Fig. 1 The crystal structure of [Zn3(bdc)2(dfp)2]2DMF 1, showing (a) the infinite
SBUs and (b) linking of the SBUs into the network.
Fig. 2 The crystal structure of [Zn3(bdc)2(dfp)2(H2O)2] 2, showing (a) the infinite
SBUs and (b) linking of the SBUs into the network.
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from 1 was investigated by both acid digestion and ligand exchange
reactions. Compound 1 dissolves in dilute hydrochloric acid, and
following dissolution in DCl–D2O and DMSO-d6, the
1H NMR
spectrum, recorded straightaway, confirmed a 1 :1 ratio of Hdfp
and H2bdc in solution. On treatment with hydrophilic solvents,
viz. phosphate buffered saline (PBS buffer), HCl–PBS buffer (pH 5.5),
1 N HCl or saturated citric acid solution, the immediate release of
deferiprone was also observed, as witnessed by elution in the LCMS
at 0.52 min, with a corresponding m/z of 140.2 (calc. for H2dfp
+,
140.1). Intriguingly, a suspension of 1 in a 1 :1 mixture of methanol
and ethanoic acid (or neat ethanoic acid) led initially to only a trace
of deferiprone (by LCMS), though after 20 min the UV intensity of
the deferiprone has increased significantly, even more so after
55 min. This demonstrates proof of concept for the potential future
employment ofMOFs as drug release platforms, although the release
properties of the MOFs need optimisation. It should be stressed that
MOFs themselves are insoluble, and can only be dissolved by
decomposition into the component parts. As such, they can be
considered as potential depots for deferiprone. The cytotoxicity of
deferiprone is well established20 and H2bdc, released with it, has low
toxicity;21 indeed, the drug oxycodone is sometimes delivered as a
salt of this acid.
Treatment of a suspension of 1 with [Fe(acac)3] (Hacac =
pentane-2,4-dione) in DMF at 40 1C for 48 h gave no reaction,
however on acidification of the solution with dilute hydrochloric
acid, deferiprone was released as the MOF decomposes and is
trapped in the form of [Fe(dfp)3], as witnessed by mass spectro-
metry of the product (m/z = 471.1076, calc. 471.1093 for [M + H]+,
493.0921, calc. 493.0912 for [M + Na]+).
FeðacacÞ3
  !1
H3O
þ
FeðdfpÞ3
 
In conclusion, we have demonstrated that following deprotona-
tion, deferiprone can be included as a ligand in zinc metal–organic
frameworks, forming both two- and three-dimensional networks. It
adopts a bidentate coordination geometry, reducing the connectivity
of the SBUs, generating frameworks with rhomboidal pores. Defer-
iprone can be released from theMOFs by treatment with PBS or acid,
with the rate of release affected by the nature of the acid employed.
Current studies are aimed at broadening the type of MOF structures
that can incorporate deferiprone as ameans of controlling their drug
release properties, and results will be reported in due course.
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(a) the tri-zinc SBUs and (b) linking of the SBUs into sheets.
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